29th Napa Pain Conference

Collapse All

Reset

Filter by Track

Filter by Tag

Multimodal Assessment of Spinal and Supraspinal Sensitization in Patients with Chronic Low Back Pain
Laura Sirucek, MSc, Author, PhD Trainee, Integrative Spinal Research Group, Balgrist University Hospital; Brigitte Wirth, PhD, Author, Senior Researcher, University of Applied Sciences; Mirjam Baechler, DC, MMEd, Author, Clinical Researcher, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich; Lucas Tauschek, BSc, Author, Research Assistant, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich; Anke Langenfeld, PhD, Author, Postdoc, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich; Leonie Hofstetter, DCM, Author, Clinical Fellow, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich; Melanie Haeusler, MChiroMed, Author, Clinical Fellow, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich; Niklaus Zoelch, PhD, Author, Research Assistant, Department of Forensic Medicine and Imaging, Institute of Forensic Medicine, University of Zurich; Prof. Christian Beckmann, PhD, Author, Principal Investigator, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center; Dr. Petra Schweinhardt, MD, PhD, Author, Head of Research, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich
Track: Poster
Tags: Clinical Research Low Back Pain Central Sensitization Neuroimaging Oral Poster

View Poster

Synopsis

A hyperexcitable central nervous system, i.e. central sensitization, is a potential pathophysiological mechanism contributing to chronic pain. This study aims to advance the understanding of central sensitization in patients with chronic low back pain (CLBP) using psychophysical assessments and brain imaging methods. Preliminary results of 31 CLBP patients suggest that psychophysical measures of spinal and supraspinal pain modulation depend on used stimulus modality and body region, i.e., painful versus non-painful body region. A multimodal approach integrating the psychophysical assessments with brain imaging measures might provide novel insights into central sensitization in CLBP.

Disclosures

The authors have no conflict of interest – financial or otherwise – to declare.
This study is funded by the Clinical Research Priority Program University of Zurich CRPP “Pain”
BW was supported by the Swiss Association of Chiropractic "ChiroSuisse"

Author(s):

Laura Sirucek, MSc, PhD Trainee, Integrative Spinal Research Group, Balgrist University Hospital
Brigitte Wirth, PhD, Senior Researcher, University of Applied Sciences
Mirjam Baechler, DC, MMEd, Clinical Researcher, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich
Lucas Tauschek, BSc, Research Assistant, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich
Anke Langenfeld, PhD, Postdoc, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich
Leonie Hofstetter, DCM, Clinical Fellow, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich
Melanie Haeusler, MChiroMed, Clinical Fellow, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich
Niklaus Zoelch, PhD, Research Assistant, Department of Forensic Medicine and Imaging, Institute of Forensic Medicine, University of Zurich
Prof. Christian Beckmann, PhD, Principal Investigator, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center
Dr. Petra Schweinhardt, MD, PhD, Head of Research, Integrative Spinal Research Group, Balgrist University Hospital, University of Zurich

Track: Poster

Tags: Clinical Research Low Back Pain Central Sensitization Neuroimaging Oral Poster

Altered Neurochemical Ratio in the Prefrontal Cortex is Associated with Pain in Fibromyalgia Syndrome
James H. Bishop, PhD, Author, Postdoctoral Fellow, Stanford University; Afik Faerman, BA, Author, Graduate Student, Stanford University; Andrew Geoly, MS, Author, Clinical Research Assistant, Stanford University; Adi Maron-Katz, PhD, Author, Postdoctoral Fellow, Stanford University; Matthew D. Sacchet, PhD, Author, Instructor, Center for Depression, Anxiety, and Stress Research, McLean Hospital, Harvard Medical School; David Spiegel, MD, Author, Professor, Department of Psychiatry & Behavioral Sciences, Stanford University; Dr. Nolan R. Williams, MD, Author, Director of the Stanford Brain Stimulation Lab, Stanford Hospital and Clinics
Track: Poster

View Poster

Synopsis

The central mechanisms underlying Fibromyalgia syndrome remain undetermined; however, there is increasing evidence to suggest that neurochemical imbalances may play a critical role in the pathophysiology of the condition. The DLPFC is a heterogeneous cortical structure involved in cognitive, affective, and sensory processing of pain known to mediate top down pain modulation. We provide the first evidence of excitatory/inhibitory imbalance within the DLPFC in fibromyalgia syndrome, which we demonstrated to be positively associated with acute/clinical pain measures and the degree of resting state functional connectivity to affective pain circuitry (dorsal anterior cingulate cortex). Together these results suggest a dysregulation of excitation and inhibition in top-down pain modulatory networks with potential pathophysiological implications in pain processing. Furthermore, this evidence provides potential pharmacological and neuromodulatory therapeutic targets for the treatment of fibromyalgia syndrome.

Disclosures

Nothing to disclose by any authors.

Author(s):

James H. Bishop, PhD, Postdoctoral Fellow, Stanford University
Afik Faerman, BA, Graduate Student, Stanford University
Andrew Geoly, MS, Clinical Research Assistant, Stanford University
Adi Maron-Katz, PhD, Postdoctoral Fellow, Stanford University
Matthew D. Sacchet, PhD, Instructor, Center for Depression, Anxiety, and Stress Research, McLean Hospital, Harvard Medical School
David Spiegel, MD, Professor, Department of Psychiatry & Behavioral Sciences, Stanford University
Dr. Nolan R. Williams, MD, Director of the Stanford Brain Stimulation Lab, Stanford Hospital and Clinics

Track: Poster

Sustained Benefits of 10kHz Spinal Cord Stimulation for Painful Diabetic Neuropathy-6-Month Randomized Controlled Trial Results
Dr. Erika A. Petersen, MD, Author, Director of the Section of Functional and Restorative Neurosurgery, Department of Neurosurgery, University of Arkansas for Medical Sciences; Dr. Thomas G. Stauss, MD, Author, Co- Owner & Attending Physician, Advanced Pain Management; Dr. James A. Scowcroft, MD, Author, Pain Management Associates; Dr. Judith L. White, MD, Author, Medical Director, AES Compass Orlando; Dr. Shawn M. Sills, MD, Author, Medical Director, Touchstone Interventional Pain Center; Dr. Kasra Amirdelfan, MD, Author, Interventional Pain Management Physician, IPM Medical Group; Dr. Maged N. Guirguis, MD, Author, Division System Lead - Interventional Pain Management, Ochsner Health System; Dr. Jijun Xu, MD, PhD, Author, Pain Management Physician, Department of Pain Management, Cleveland Clinic Foundation; Dr. Cong Yu, MD, Author, Pain Medicine Physician, Swedish Health Services; Ali Nairizi, MD, Author, Nevada Advanced Pain Specialists; Denis G. Patterson, DO, Author, Nevada Advanced Pain Specialists; Vincent Galan, MD, Author, Pain Care; Richard H. Bundschu, MD, Author, Interventional Pain Management Specialist, Coastal Orthopedics and Sports Medicine; Neel D. Mehta, MD, Author, Department of Anesthesiology, Weill Cornell Medical College; Dr. Dawood Sayed, MD, Author, Department of Anesthesiology and Pain Medicine, University of Kansas Medical Center; Dr. Shivanand P. Lad, MD, PhD, Author, Department of Neurosurgery, Duke University; David J. DiBenedetto, MD, Author, Boston PainCare; Khalid A. Sethi, MD, Author, Department of Neurosurgery, United Health Services; Dr. Paul W. Wu, MD, Author, Interventional Physiatrist, Holy Cross Hospital; Dr. Charles E. Argoff, MD, Author, Department of Neurology, Albany Medical Center; Christian E. Nasr, MD, Author, Department of Endocrinology, Cleveland Clinic Foundation; Rod S. Taylor, MSc, PhD, Author, Institute of Health and Well Being, University of Glasgow; Dr. David L. Caraway, MD, PhD, Author, Chief Medical Officer, Nevro, Inc.; Dr. Nagy A. Mekhail, MD, PhD, Author, Carl Wasmuth Chair in Anesthesiology, Cleveland Clinic
Track: Poster
Tags: Bioelectronic Medicine Interventional Pain Management Endocrinology

View Poster

Synopsis

In the largest RCT of SCS for painful diabetic neuropathy (PDN), 216 patients with symptoms refractory to conventional treatments were randomized 1:1 to continue with conventional medical management (CMM) alone or add 10 kHz SCS to CMM. Outcomes are durable to 6-month follow-up with 5.4% (5/93) of CMM subjects as pain responders compared with 85.1% (74/87) of 10 kHz SCS+CMM subjects (p < 0.001). Investigators observed sensory improvements in 3.3% (3/92) of CMM subjects versus 61.9% (52/84) of 10 kHz SCS+CMM subjects (p < 0.001). This study provides Level I evidence for high frequency SCS to treat PDN patients with refractory symptoms.

Disclosure

Study funded by Nevro Corp.

Categories

Clinical advancements in pain management,
Bioelectronic medicine

Author(s):

Dr. Erika A. Petersen, MD, Director of the Section of Functional and Restorative Neurosurgery, Department of Neurosurgery, University of Arkansas for Medical Sciences
Dr. Thomas G. Stauss, MD, Co- Owner & Attending Physician, Advanced Pain Management
Dr. James A. Scowcroft, MD, Pain Management Associates
Dr. Judith L. White, MD, Medical Director, AES Compass Orlando
Dr. Shawn M. Sills, MD, Medical Director, Touchstone Interventional Pain Center
Dr. Kasra Amirdelfan, MD, Interventional Pain Management Physician, IPM Medical Group
Dr. Maged N. Guirguis, MD, Division System Lead - Interventional Pain Management, Ochsner Health System
Dr. Jijun Xu, MD, PhD, Pain Management Physician, Department of Pain Management, Cleveland Clinic Foundation
Dr. Cong Yu, MD, Pain Medicine Physician, Swedish Health Services
Ali Nairizi, MD, Nevada Advanced Pain Specialists
Denis G. Patterson, DO, Nevada Advanced Pain Specialists
Vincent Galan, MD, Pain Care
Richard H. Bundschu, MD, Interventional Pain Management Specialist, Coastal Orthopedics and Sports Medicine
Neel D. Mehta, MD, Department of Anesthesiology, Weill Cornell Medical College
Dr. Dawood Sayed, MD, Department of Anesthesiology and Pain Medicine, University of Kansas Medical Center
Dr. Shivanand P. Lad, MD, PhD, Department of Neurosurgery, Duke University
David J. DiBenedetto, MD, Boston PainCare
Khalid A. Sethi, MD, Department of Neurosurgery, United Health Services
Dr. Paul W. Wu, MD, Interventional Physiatrist, Holy Cross Hospital
Dr. Charles E. Argoff, MD, Department of Neurology, Albany Medical Center
Christian E. Nasr, MD, Department of Endocrinology, Cleveland Clinic Foundation
Rod S. Taylor, MSc, PhD, Institute of Health and Well Being, University of Glasgow
Dr. David L. Caraway, MD, PhD, Chief Medical Officer, Nevro, Inc.
Dr. Nagy A. Mekhail, MD, PhD, Carl Wasmuth Chair in Anesthesiology, Cleveland Clinic

Track: Poster

Tags: Bioelectronic Medicine Interventional Pain Management Endocrinology

Patient Preferences to Inform Non-Surgical Treatment Choice for the Best Outcomes for Chronic Low Back Pain (cLBP)
Leslie Wilson, PhD, Author, Professor, Health Economics, UCSF; Jeffrey C. Lotz, PhD, Author, David S. Bradford M.D. Endowed Chair in Orthopaedic Surgery and Vice Chair of Research, UCSF; Dr. Patricia Zheng, MD, Author, Assistant Professor, of Orthopaedic Surgery, UCSF; Alina Denham, Author, University of Rochester; Yelena Ionova, PharmD, Author, Fellow, UCSF; Connie Yoo, PharmD, Author, UCSF; Yanlei Ma, PhD, Author, Statistician, Cornell University; Conor O'Neill, MD, Author, Professor, Department of Orthopaedic Surgery, UCSF; Carol M. Greco, PhD, Author, Associate Professor, Psychiatry, Rehabilitation Science, Technology, & Physical Therapy, University of Pittsburgh; Janel Hanmer, MD, PhD, Author, Associate Professor, General Internal Medicine, University of Pittsburgh; David A. Williams, PhD, Author, Professor, Anesthesiology, Medicine and Psychiatry, University of Michigan; Afton Hassett, PsyD, Author, Associate Professor, Anesthesiology, University of Michigan; Aaron Wolfe Scheffler, PhD, Author, Epidemiology and Biostatistics, UCSF; Frank Valone, MD, Author, California Pacific Orthopaedics; Wolf Mehling, Author, Osher Center, Department of Family & Community Medicine , UCSF; Dr. Sigurd H. Berven, MD, Author, Professor in Residence, UCSF Dept of Orthopaedic Surgery
Track: Poster

View Poster

Synopsis

Understanding patient preference for cLBP treatment is useful to improve targeting of therapies and increase adherence resulting in improved outcomes. This study developed and used the first discrete choice measure of patient preferences for nonsurgical treatments. In 206 persons with cLBP, the strongest preference was for best chance & longest duration of pain relief (β=1.96, p<0.001 & β=0.90, p<0.001). Avoiding long-term side-effects (β=-0.67, p<0.001) was preferred over avoiding a rare risk of permanent, serious injury’ (β=-0.28, p=0.012). Patients strongly preferred one-on-one support from a trusted therapy provider at every session, and improvement of strength was the strongest outcome preference.xtagstartz/p>xtagstartz/p>

Author(s):

Leslie Wilson, PhD, Professor, Health Economics, UCSF
Jeffrey C. Lotz, PhD, David S. Bradford M.D. Endowed Chair in Orthopaedic Surgery and Vice Chair of Research, UCSF
Dr. Patricia Zheng, MD, Assistant Professor, of Orthopaedic Surgery, UCSF
Alina Denham, University of Rochester
Yelena Ionova, PharmD, Fellow, UCSF
Connie Yoo, PharmD, UCSF
Yanlei Ma, PhD, Statistician, Cornell University
Conor O'Neill, MD, Professor, Department of Orthopaedic Surgery, UCSF
Carol M. Greco, PhD, Associate Professor, Psychiatry, Rehabilitation Science, Technology, & Physical Therapy, University of Pittsburgh
Janel Hanmer, MD, PhD, Associate Professor, General Internal Medicine, University of Pittsburgh
David A. Williams, PhD, Professor, Anesthesiology, Medicine and Psychiatry, University of Michigan
Afton Hassett, PsyD, Associate Professor, Anesthesiology, University of Michigan
Aaron Wolfe Scheffler, PhD, Epidemiology and Biostatistics, UCSF
Frank Valone, MD, California Pacific Orthopaedics
Wolf Mehling, Osher Center, Department of Family & Community Medicine , UCSF
Dr. Sigurd H. Berven, MD, Professor in Residence, UCSF Dept of Orthopaedic Surgery

Track: Poster

Novel Multispecialty Pain and Opioid Prescribing Oversight Clinic for a Large Military Medical Treatment Facility Can Have Major Safety Ramifications
Dr. Ronald White, MD, Author, Former Chief of Pain Medicine, DGMC; Benjamin White, Author, Research Assistant; Daniel Jacobs, DO, Author, Chief of Pain Medicine, DGMC; Min Ji Ahn, PharmD, Author, DGMC; Lacey Hess, BSN, RN, Author, Former Chief Pain Nurse; Glenhall Taylor, MD, Author, Pain Psychiatrist, DGMC; Irene Mateo, MS, RN, Author, Chief Pain Nurse, DGMC; Anthony White, MS-1, Author, USUHS
Track: Poster
Tags: Pain Management Opioids

View Poster

Synopsis

Natural experiment quality improvement project with overall reduction in opioid prescriptions per 100 people by 49%. Achieving a greater reduction of opioid prescriptions than the U.S. and California each year (2016-2019) by at least 43.2% and as high as 67.5%. Categorized chronic pain patients (High Dose (HD), Moderate Dose (MD), Low Dose (LD) and Very Low Dose (VLD) defined by morphine equivalents of ³90, 50-89, 20-49) were reduced by 63.6%, 65.2%, 53.1% and 59.3% respectively. Categorized acute pain patients classified by Day’s Supply (DS) of opioid medication (1-8, 9-17 and > 18 DS) had reductions of 36.5%, 73.1% and 80.7% respectively.

Disclosures

Nothing to disclose by any author

Author(s):

Dr. Ronald White, MD, Former Chief of Pain Medicine, DGMC
Benjamin White, Research Assistant
Daniel Jacobs, DO, Chief of Pain Medicine, DGMC
Min Ji Ahn, PharmD, DGMC
Lacey Hess, BSN, RN, Former Chief Pain Nurse
Glenhall Taylor, MD, Pain Psychiatrist, DGMC
Irene Mateo, MS, RN, Chief Pain Nurse, DGMC
Anthony White, MS-1, USUHS

Track: Poster

Tags: Pain Management Opioids

Approved OIC Medication use in Emergency Department Patients With Opioid-Induced Constipation
Dr. W. Frank Peacock, MD, Author, Vice Chair for Research, Henry JN Taub Department of Emergency Medicine; Dr. Neal E. Slatkin, MD, Author, Director, Medical Affairs, Salix Pharmaceuticals; Patrick Gagnon-Sanschagrin, MSc, Author, Manager, Analysis Group, Inc; Jessica Maitland, MScPH, Author, Senior Research Professional, Analysis Group, Inc; Annie Guérin, MSc, Author, Managing Principal, Analysis Group, Inc; George Joseph, PhD, Author, Vice President, Health Economics & Outcomes Research, Bausch Health US, LLC
Track: Poster

View Poster

Synopsis

Real-world evidence concerning the use of prescription treatments for opioid-induced constipation (OIC) in the emergency department (ED) is lacking. This retrospective analysis compared healthcare resource utilization in hospitals and healthcare costs among patients reporting to the ED who received OIC treatment (n=11,135, 93% used methylnaltrexone SC) versus those who did not (n=21, 474). Overall, patients who received prescription OIC treatment were more likely to be discharged home, less likely to be hospitalized, had a reduced hospital stay, and a mean of $1152 less in total healthcare costs per ED encounter than patients who did not receive prescription OIC treatment.

Disclosures

WFP has received research grants from Abbott, Boehringer Ingelheim, Braincheck, CSL Behring, Daiichi-Sankyo, ImmunArray, Janssen, Ortho Clinical Diagnostics, Portola, Relypsa, and Roche. He serves as a consultant for Abbott, AstraZeneca, Bayer, Beckman, Boehringer Ingelheim, Ischemia Care, LLC, ImmunArray, Instrument Labs, Janssen, Nabriva, Ortho Clinical Diagnostics, Relypsa, Roche, Quidel, Salix, and Siemens. He has provided expert testimony for Johnson & Johnson and has stock/ownership interests in AseptiScope Inc, Brainbox Inc, Comprehensive Research Associates LLC, Emergencies in Medicine LLC, and Ischemia Care, LLC.
NES is an employee of Salix Pharmaceuticals, a subsidiary of Bausch Health US, LLC.
PGS, JM, and AG are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Bausch Health US, LLC., which funded the development and conduct of this study.
GJ is a full-time employee and shareholder of Bausch Health US, LLC.

Author(s):

Dr. W. Frank Peacock, MD, Vice Chair for Research, Henry JN Taub Department of Emergency Medicine
Dr. Neal E. Slatkin, MD, Director, Medical Affairs, Salix Pharmaceuticals
Patrick Gagnon-Sanschagrin, MSc, Manager, Analysis Group, Inc
Jessica Maitland, MScPH, Senior Research Professional, Analysis Group, Inc
Annie Guérin, MSc, Managing Principal, Analysis Group, Inc
George Joseph, PhD, Vice President, Health Economics & Outcomes Research, Bausch Health US, LLC

Track: Poster

Modified Bipolar Radiofrequency Ablation in Ultrasound Guided Anterior Knee Capsule Denervation
Dr. Lynn Cintron, MD, Author, 2020-2021 President, CalSIPP; Balcazar Silver, MD, ASRA, PMUC, Author, Attending Anesthesiologist Pain Medicine, Director of Centro Médico del Dolor; Associate Professor, School of Medicine, Hospital Universitario UANL
Track: Poster
Tags: Radiofrequency Ablation Interventional Pain Medicine

View Poster

Synopsis

Osteoarthritis of the knee joint is a major cause of pain worldwide However, treatments designed to control it are insufficient. Although surgery may be indicated, many older patients are inappropriate surgical candidates. Radiofrequency ablation is an effective pain treatment especially when performed following new insights on 3 dimensional human anatomy This is relevant for improved ablation of nerves supplying the knee joint The technique presented addresses this important issue by following the anatomical distribution of innervation It effectively arranges the cannulas by performing a non-traditional approach and places them in a sagittal plane one in front of the other for a larger lesion.

Disclosures

Nothing to disclose by any author.

Author(s):

Dr. Lynn Cintron, MD, 2020-2021 President, CalSIPP
Balcazar Silver, MD, ASRA, PMUC, Attending Anesthesiologist Pain Medicine, Director of Centro Médico del Dolor; Associate Professor, School of Medicine, Hospital Universitario UANL

Track: Poster

Tags: Radiofrequency Ablation Interventional Pain Medicine

NIH HEAL Initiative: National Institute of Neurological Disorders and Stroke’s Early Phase Pain Investigation Clinical Network (EPPIC-Net)
Barbara I. Karp, MD, Author, Program Director, National Institute of Neurological Disorders and Stroke; Rebecca Hommer, MD, Author, Program Director, National Institute of Neurological Disorders and Stroke; Marlene Peters Lawrence, RN, Author, Program Manager, National Institute of Neurological Disorders and Stroke; Jennifer Beierlein, PhD, Author, Health Program Specialist, National Institute of Neurological Disorders and Stroke; Tjerignimin Adissa Silue, PhD, Author, Scientific Program Manager, National Institute of Neurological Disorders and Stroke; Dr. Clinton B. Wright, MD, Author, Director of the Division of Clinical Research, National Institutes of Health (NIH)
Track: Poster

View Poster

Synopsis

The NIH HEAL (Helping to End Addiction Long-term) SM Initiative is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Within the HEAL initiative, NINDS developed the Early Phase Pain Investigation Clinical Network (EPPIC-Net) to focus on understanding pain mechanisms and developing effective, non-addictive treatments for pain by carrying-out phase 2 clinical trials of novel, non-addictive pain therapies. EPPIC-NET accepts application on a rolling basis. Academic and industry researchers from the USA and internationally are welcome to apply.

Disclosures

Nothing to disclose by any authors.

Author(s):

Barbara I. Karp, MD, Program Director, National Institute of Neurological Disorders and Stroke
Rebecca Hommer, MD, Program Director, National Institute of Neurological Disorders and Stroke
Marlene Peters Lawrence, RN, Program Manager, National Institute of Neurological Disorders and Stroke
Jennifer Beierlein, PhD, Health Program Specialist, National Institute of Neurological Disorders and Stroke
Tjerignimin Adissa Silue, PhD, Scientific Program Manager, National Institute of Neurological Disorders and Stroke
Dr. Clinton B. Wright, MD, Director of the Division of Clinical Research, National Institutes of Health (NIH)

Track: Poster

Long-Term Outcomes Using an SCS System Capable of Combination Therapy: A Randomized Controlled Trial (COMBO)
Mark Wallace, MD, Author, University of California, San Diego
Track: Poster

View Poster

Synopsis

We endeavored to investigate outcomes associated with use of multiple neurostimulation modalities as compared with conventional SCS settings alone in a prospective, randomized controlled trial. The primary endpoint was proportion of subjects permanently implanted with an SCS system capable of multiple neurostimulation modalities demonstrating 50% or greater reduction in average overall pain intensity at 3-months post-randomization. The study met its primary endpoint based on a pre-specified cohort of 89 randomized subjects (p<0.001). The results provide further support for the advantages of using neuromodulation systems capable of patient-specific stimulation options that enable highly customized therapy for treatment of chronic pain.

Disclosures

Drs. Wallace, North, Washabaugh, Lee, Phillips, and Trainor have consulting agreements with Boston Scientific.
Lilly Chen and Roshini Jain are employees of Boston Scientific.

Author(s):

Mark Wallace, MD, University of California, San Diego

Track: Poster

Long-Term Pain Relief Using an SCS Device Capable of Simultaneous Combination Therapy and Dorsal Horn Modulation
Clark S. Metzger, MD, Author, NeuroMicroSpine; M. Blake Hammond, PA, Author, NeuroMicroSpine; Stephen T. Pyles, MD, Author, Pain Treatment Centers; Dr. Edward P. Washabaugh III, MD, FIPP, Author, Forest Health Medical Center; Dr. Romanth Waghmarae, MD, DABA, FIPP, Author, Medical Director, Advanced Pain and Wellness Institute; Anthony P. Berg, MD, Author, Spine Team Texas; James M. North, MD, Author, The Center for Clinicial Research, LLC; Yu Pei, MPA, Author, Boston Scientific; Roshini Jain, MS, Author, Boston Scientific
Track: Poster

View Poster

Synopsis

As more SCS systems that provide multiple neurostimulation approaches continue to become available, it will be necessary to evaluate usage of these devices and associated clinical outcomes. In this study, long-term outcomes were assessed in patients using a new SCS system designed to customize SCS using combination therapy, waveform automation, and a device algorithm engineered for manipulatable control of stimulation field shape. Twenty-three percent of all patients reported being pain free (NRS = 0) at last follow-up. Given the variability of experience associated with chronic pain, the SCS-implanted patient population may particularly benefit from devices that enable individualized treatment customization.

Disclosures

Mr. Hammond reports personal fees from Orthomicrospine and personal fees from Boston Scientific.
Dr. Pyles has received speaker honoraria from and is a consultant for Boston Scientific.
Dr. Waghmarae is a consultant for Boston Scientific. Dr. North is a consultant for Boston Scientific.
Dr. Berg is a consultant for Boston Scientific.
Drs. Metzger and Washabaugh report no relevant conflicts of interest.
Ms. Jain and Ms. Pei are salaried employees of Boston Scientific.
This study was sponsored by Boston Scientific.

Author(s):

Clark S. Metzger, MD, NeuroMicroSpine
M. Blake Hammond, PA, NeuroMicroSpine
Stephen T. Pyles, MD, Pain Treatment Centers
Dr. Edward P. Washabaugh III, MD, FIPP, Forest Health Medical Center
Dr. Romanth Waghmarae, MD, DABA, FIPP, Medical Director, Advanced Pain and Wellness Institute
Anthony P. Berg, MD, Spine Team Texas
James M. North, MD, The Center for Clinicial Research, LLC
Yu Pei, MPA, Boston Scientific
Roshini Jain, MS, Boston Scientific

Track: Poster

Synopsis

Disclosure

Categories

No contact info to display.